Nephrology
Latest news
146 articles · 20 / page
Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds
In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or th
Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction
This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF
Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction
This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.
SGLT2 Inhibitors Remain Protective Even After Severe eGFR Decline: Pooled Trial Analysis Across Cardio‑Renal‑Metabolic Populations
A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (
Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker
An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart fai
PAD4, NETs, and Inflammasome Activation: A New Mechanistic Link Between Diabetes and Cardiorenal Injury
A translational study links hyperglycaemia-driven PAD4-dependent neutrophil extracellular trap (NET) formation and inflammasome activation to cardiac and renal inflammation, fibrosis, and heart failure in experimental diabetes—suggesting no
Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety
The MIRO‑CKD phase 2b trial found that adding the non‑steroidal MRA balcinrenone to dapagliflozin reduced albuminuria versus dapagliflozin alone in people with CKD, with dose‑dependent effects and modest hyperkalaemia rates over 12 weeks.
Biomarker-Guided Preventive Care Halves Risk of Moderate–Severe AKI After Major Surgery: Results from BigpAK-2
In BigpAK-2, a multinational randomized trial, a KDIGO-based preventive bundle triggered by tubular stress biomarkers reduced moderate or severe acute kidney injury within 72 hours after major surgery (OR 0.57; NNT 12) without increasing ad
Unequal and Multisystem Mortality Risks After Tropical Cyclones: Renal, Injury, Infectious and Chronic Disease Burdens Across Nine Countries
A multinational time-series study across nine countries found increased short-term mortality after tropical cyclones for multiple causes — highest for renal disease and injuries — with larger effects in deprived and cyclone-naïve communitie
Acute Kidney Injury in Extremely Preterm Infants Predicts Higher Risk of Death or Neurodevelopmental Impairment at Two Years
Secondary analysis of the PENUT trial found that acute kidney injury (AKI) in infants born at 24–27 weeks’ gestation is independently associated with death or moderate to severe neurodevelopmental impairment at 22–26 months’ corrected age.
Temporary Inpatient Hemodialysis Access for Uninsured Patients Is Associated with Shorter Hospital Stays in a County Safety-Net System
A Los Angeles County quality-improvement study found that regulatory approval allowing an inpatient hemodialysis unit to provide transitional outpatient dialysis to uninsured patients initiating hemodialysis was associated with a substantia
Community Health Workers Reduce Interdialytic Weight Gain and Improve Engagement Among Hispanic/Latino Hemodialysis Patients: Results from the Navigate‑Kidney RCT
A randomized trial found that a culturally tailored community health worker (CHW) intervention modestly reduced interdialytic weight gain, improved dialysis adherence, and increased patient activation among Hispanic and Latino adults receiv
The Vanishing Female Survival Advantage in Stage 5 CKD: Higher Mortality and Lower Receipt of Kidney Replacement Therapy Among Women
In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, indepe
Clinical Decision Support Tool May Improve ACEI and ARB Use in CKD
A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.
Albuminuria Reduction and GFR Total-Slope Strongly Predict Kidney Failure: Surrogate Endpoints in CKD Trials
Large individual-patient meta-analyses show that 6-month albuminuria reduction and 3-year total GFR slope predict kidney failure across CKD populations—supporting their use as surrogate endpoints in randomized trials with caveats for chroni
Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk
The GBD 2023 analysis estimates 788 million adults living with chronic kidney disease in 2023, rising since 1990, with CKD a top-10 cause of death and a major contributor to cardiovascular mortality. Urgent action on screening, prevention,
Atacicept Cuts Proteinuria in IgA Nephropathy — How Emerging B‑cell and Complement‑Targeted Therapies Compare
A prespecified interim analysis of a phase 3 trial shows atacicept produced a 45.7% proteinuria reduction versus 6.8% with placebo at 36 weeks. Phase 2 data for sibeprenlimab, cemdisiran, and felzartamab also show promising antiproteinuric
Fish-Oil Supplementation Halves Serious Cardiovascular Events in Hemodialysis Patients: Results from the PISCES Randomized Trial
A double-blind randomized trial (PISCES) found daily fish-oil (EPA+DHA) 4 g reduced serious cardiovascular events by 43% versus corn-oil placebo in patients on maintenance hemodialysis over 3.5 years.
Finerenone Lowers Albuminuria in Type 1 Diabetes with CKD: FINE‑ONE Phase III Shows 25% Average UACR Reduction and Acceptable Safety
The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type
SGLT2 Inhibitors Reduce Kidney Events, Hospitalization and Death Regardless of Diabetes or Albuminuria: A SMART-C Meta-Analysis Interpretation
A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.
Browse by specialty
Open language-specific specialty feeds and department pages.